Clinical trialsCompany release
PMV Pharma reports 48% response rate for rezatapopt in platinum-resistant ovarian cancer
🇺🇸 PMV Pharmaceuticals, Inc. (PMVP) · Fri 20 Nov 2026
Updated pivotal PYNNACLE data in TP53 Y220C-mutated tumours support a planned accelerated approval filing for platinum-resistant or refractory ovarian cancer in the first quarter of 2027.
PMV Pharmaceuticals presented updated results from the pivotal Phase 2 PYNNACLE trial on 20 November 2026 at ENA 2026 in Barcelona. The study tests rezatapopt as monotherapy in advanced solid tumours carrying the TP53 Y220C mutation.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): PMV Pharmaceuticals, Inc. ↗
Article written by VigiEye from the official source (PMV Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
J&J's Tremfya beats placebo in Phase 4 STAR axial psoriatic arthritis study at Week 24
Johnson & Johnson EMEA · Fri 20 Nov 2026
Immutep reports 81% 12-month disease-free survival in neoadjuvant soft tissue sarcoma trial
IMMUTEP Ltd (IMMP) · Fri 20 Nov 2026
BfArM lists ArcRoyal field safety notice for procedure trays containing BD Connecta Stopcock
🇩🇪 BfArM field safety notices · Thu 19 Nov 2026
FDA allows Alpha Tau to double REGAIN glioblastoma trial to 20 patients
Alpha Tau Medical Ltd. (DRTS) · Thu 19 Nov 2026
Health Canada posts Type II recall of Philips Bridge Prep Kit over guidewire resistance
🇨🇦 Health Canada · Thu 19 Nov 2026
Olympus updates reprocessing instructions for GF-UC140P-AL5 endoscopic ultrasound gastrovideoscopes in Canada
🇨🇦 Health Canada · Thu 19 Nov 2026